Outset Medical, Inc.

NasdaqGS OM

Outset Medical, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -121.02 M

Outset Medical, Inc. EBIT is USD -121.02 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 26.12% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Outset Medical, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -163.81 M, a -1.90% change year over year.
Outset Medical, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -160.76 M, a -32.07% change year over year.
Outset Medical, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -121.72 M, a -15.48% change year over year.
Outset Medical, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -105.40 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: OM

Outset Medical, Inc.

CEO	Ms. Leslie L. Trigg
IPO Date	Sept. 15, 2020
Location	United States
Headquarters	3052 Orchard Drive
Employees	480
Sector	Health Care
Industries Pharmaceuticals Medical Instruments Telehealth

Description

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Key trends

Past 5 years